Journal for ImmunoTherapy of Cancer (Nov 2023)
438 In vivo Engineered CAR-T cells for oncology using a surface-engineered lentivirus platform: nonclinical safety and biodistribution
- Andrew Scharenberg,
- Ryan Larson,
- Alyssa Sheih,
- Mason Muhonen,
- Jessica Freeman,
- Sarah Gould,
- Rich Getto,
- Alessandra M Sullivan,
- Susana Hernandez,
- Kathryn Michels,
- Byoung Ryu,
- Alissa Brandes,
- Soo Min Koo,
- Don Parilla,
- Christopher Nicolai,
- Anna Ting,
- Tim Gervascio,
- Nanda Coelho,
- Anai Perez,
- Jeff Teoh
Affiliations
- Andrew Scharenberg
- Aff1 Cellectis Therapeutics Paris France
- Ryan Larson
- Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA
- Alyssa Sheih
- 1Umoja Biopharma, Seattle, WA, USA
- Mason Muhonen
- MSAT, Umoja Biopharma, Boulder, Colorado, USA
- Jessica Freeman
- MSAT, Umoja Biopharma, Boulder, Colorado, USA
- Sarah Gould
- MSAT, Umoja Biopharma, Boulder, Colorado, USA
- Rich Getto
- Umoja Biopharma, Seattle, Washington, USA
- Alessandra M Sullivan
- Immunology, Umoja Biopharma Inc, Seattle, Washington, USA
- Susana Hernandez
- Umoja Biopharma, Seattle, WA, USA
- Kathryn Michels
- Umoja Biopharma, Seattle, WA, USA
- Byoung Ryu
- Umoja Biopharma, Seattle, WA, USA
- Alissa Brandes
- Umoja Biopharma, Seattle, WA, USA
- Soo Min Koo
- Umoja Biopharma, Seattle, WA, USA
- Don Parilla
- Umoja Biopharma, Seattle, WA, USA
- Christopher Nicolai
- Umoja Biopharma, Seattle, WA, USA
- Anna Ting
- Umoja Biopharma, Seattle, WA, USA
- Tim Gervascio
- Umoja Biopharma, Seattle, WA, USA
- Nanda Coelho
- Umoja Biopharma, Seattle, WA, USA
- Anai Perez
- Umoja Biopharma, Seattle, WA, USA
- Jeff Teoh
- Umoja Biopharma, Seattle, WA, USA
- DOI
- https://doi.org/10.1136/jitc-2023-SITC2023.0438
- Journal volume & issue
-
Vol. 11,
no. Suppl 1
Abstract
No abstracts available.
